| ||Audit Committee||Nominating and Governance Committee||Compensation Committee||Research and Development Strategy Committee|
|Louis C. Bock |
|Louis C. Bock|
Director, Scale Venture Partners
Louis C. Bock has served as a member of our board of directors since April 2005. Mr. Bock is Venture Partner at Santé Ventures, which he joined in 2014. Prior to joining Santé, Lou was a Partner and Co-Founder of Scale Venture Partners from 1997-2014. He was a member of the healthcare team and built the firm’s biotech practice. Lou joined Scale in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. Prior to Gilead, he was a researc...
|| || |
|Brian H. Dovey |
|Brian H. Dovey|
Director, Domain Associates (Partner)
Mr. Dovey has served as a member of our board of directors since January 2004. Mr. Dovey is a managing member of Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, and has served in this capacity with the firm since 1988. He has served as chairman of three companies and on the board of directors of approximately 30 additional companies, including Align Technology, Inc. and Cardiac Science, Inc. Mr. Dovey currently serves on the board of Neose Technolog...
| || ||
|David J. Endicott |
|David J. Endicott|
David J. Endicott has served as a member of our board of directors since November 2012. Mr. Endicott currently serves as the President of Hospira Medical Devices, a global pharmaceutical company. Prior to this position, Mr. Endicott served as Corporate Vice President and President, Allergan Medical, Asia Pacific and Latin America from April 2011 through July 2013 and served as Corporate Vice President and President, Allergan Medical from August 2010 through April 2011. Prior to that, he served a...
|| || |
|Peter K. Honig, M.D., M.P.H. |
|Peter K. Honig, M.D., M.P.H.|
Peter Honig is Senior Vice President of Worldwide Regulatory Affairs at Pfizer. Dr. Honig received his baccalaureate, medical and public health degrees from Columbia University in New York. He has postgraduate training and is board-certified in internal medicine and clinical pharmacology and has authored numerous peer reviewed publications, invited commentaries, and book chapters. Previous experience includes senior leadership positions at the United States Food and Drug administration, Merck Re...
| || || ||
|Deborah A. Jorn |
|Deborah A. Jorn|
Deborah A. Jorn has served as a member of our board of directors since 2016. Ms. Jorn is a senior commercial strategist with a more than 30-year history of building multi-billion dollar global pharmaceutical businesses and a proven track record of designing and implementing innovative business and marketing strategies that have consistently delivered double-digit organic growth across numerous therapeutic areas. Ms. Jorn is the former Executive Vice President and Group Company Chair at Valeant P...
| || || || |
|Patrick J. Mahaffy |
|Patrick J. Mahaffy|
Chairman of the Board of Directors
Patrick J. Mahaffy has served as a member of our board of directors since February 2009, and as the chairman of the board of directors since April 2016. Mr. Mahaffy is a founder of Clovis Oncology, Inc. and has served as President and Chief Executive Officer and a member of its board of directors since its inception. Previously, Mr. Mahaffy served in the same role at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was Pr...
|Lota S. Zoth, CPA
|Lota S. Zoth, CPA|
Lota S. Zoth, CPA has served as a member of our board of directors since April 2012. Ms. Zoth served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. from April 2004 to July 2007 and also served as its Controller and Principal Accounting Officer. Prior to joining MedImmune in 2002, Ms. Zoth served as Senior Vice President, Corporate Controller and Principal Accounting Officer at PSINet Inc., Vice President, Corporate Controller and Chief Accounting Officer at Sodexho Marri...
|Michael A. Narachi |
|Michael A. Narachi|
President and Chief Executive Officer, Orexigen
Michael A. Narachi has served as our President and Chief Executive Officer and a member of our board of directors since March 2009 . Previously, Mr. Narachi served as Chairman , Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008 , Mr.
Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Mr. Narachi retired as an of...
| || || || |